trending Market Intelligence /marketintelligence/en/news-insights/trending/d7GH6s8Otlz5omclBD6Mrg2 content esgSubNav
In This List

Valeant appoints dermatology EVP

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


Valeant appoints dermatology EVP

Valeant Pharmaceuticals International Inc. appointed William Humphries executive vice president of dermatology, effective Jan. 2, 2017.

Humphries will join the company's executive committee and report directly to Chairman and CEO Joseph Papa. Humphries recently served as CEO of the North America business of Merz GmbH & Co. KGaA.

Anne Whitaker, Rob Rosiello and Ari Kellen are also set to leave Valeant's executive team. Both Whitaker and Kellen served as executive vice president and company group chairman, while Rosiello served as the company's CFO from July 2015 through August 2016.

Whitaker will leave Jan. 13, 2017. Rosiello and Kellen, who will step down from their positions Dec. 31, will remain with the company as consultants.